Publications of Roman K. Thomas

Journal Article (72)

2011
Journal Article
Hammerman, P. S.; Sos, M. L.; Ramos, A. H.; Xu, C.; Dutt, A.; Zhou, W.; Brace, L. E.; Woods, B. A.; Lin, W.; Zhang, J. et al.; Deng, X.; Lim, S. M.; Heynck, S.; Peifer, M.; Simard, J. R.; Lawrence, M. S.; Onofrio, R. C.; Salvesen, H. B.; Seidel, D.; Zander, T.; Heuckmann, J. M.; Soltermann, A.; Moch, H.; Koker, M.; Leenders, F.; Gabler, F.; Querings, S.; Ansen, S.; Brambilla, E.; Brambilla, C.; Lorimier, P.; Brustugun, O. T.; Helland, A.; Petersen, I.; Clement, J. H.; Groen, H.; Timens, W.; Sietsma, H.; Stoelben, E.; Wolf, J.; Beer, D. G.; Tsao, M. S.; Hanna, M.; Hatton, C.; Eck, M. J.; Janne, P. A.; Johnson, B. E.; Winckler, W.; Greulich, H.; Bass, A. J.; Cho, J.; Rauh, D.; Gray, N. S.; Wong, K.-K.; Haura, E. B.; Thomas, R. K.; Meyerson, M.: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery 1 (1), pp. 78 - 89 (2011)
Journal Article
Heuckmann, J. M.; Hölzel, M.; Sos, M. L.; Heynck, S.; Balke-Want, H.; Koker, M.; Peifer, M.; Weiss, J.; Lovly, C. M.; Grütter, C. et al.; Rauh, D.; Pao, W.; Thomas, R. K.: ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research 17 (23), pp. 7394 - 7401 (2011)
Journal Article
Lovly, C. M.; Heuckmann, J. M.; de Stanchina, E.; Chen, H.; Thomas, R. K.; Liang, C.; Pao, W.: Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Research 71 (14), pp. 4920 - 4931 (2011)
Journal Article
Park, K.-S.; Martelotto, L. G.; Peifer, M.; Sos, M. L.; Karnezis, A. N.; Mahjoub, M. R.; Bernard, K.; Conklin, J. F.; Szczepny, A.; Yuan, J. et al.; Guo, R.; Ospina, B.; Falzon, J.; Bennett, S.; Brown, T. J.; Markovic, A.; Devereux, W. L.; Ocasio, C. A.; Chen, J. K.; Stearns, T.; Thomas, R. K.; Dorsch, M.; Buonamici, S.; Watkins, D. N.; Peacock, C. D.; Sage, J.: A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine 17 (11), pp. 1504 - 1508 (2011)
Journal Article
Querings, S.; Altmüller, J.; Ansen, S.; Zander, T.; Seidel, D.; Gabler, F.; Peifer, M.; Markert, E.; Stemshorn, K.; Timmermann, B. et al.; Saal, B.; Klose, S.; Ernestus, K.; Scheffler, M.; Engel-Riedel, W.; Stoelben, E.; Brambilla, E.; Wolf, J.; Nürnberg, P.; Thomas, R. K.: Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS ONE 6 (5), p. e19601 - e19601 (2011)
Journal Article
Zander, T.; Hofmann, A.; Staratschek-Jox, A.; Classen, S.; Debey-Pascher, S.; Maisel, D.; Ansen, S.; Hahn, M.; Beyer, M.; Thomas, R. K. et al.; Gathof, B.; Mauch, C.; Delank, K.-S.; Engel-Riedel, W.; Wichmann, H.-E.; Stoelben, E.; Schultze, J. L.; Wolf, J.: Blood-based gene expression signatures in non-small cell lung cancer. Clinical Cancer Research 17 (10), pp. 3360 - 3367 (2011)
Journal Article
Zander, T.; Scheffler, M.; Nogova, L.; Kobe, C.; Engel-Riedel, W.; Hellmich, M.; Papachristou, I.; Toepelt, K.; Draube, A.; Heukamp, L. et al.; Buettner, R.; Ko, Y. D.; Ullrich, R. T.; Smit, E.; Boellaard, R.; Lammertsma, A. A.; Hallek, M.; Jacobs, A. H.; Schlesinger, A.; Schulte, K.; Querings, S.; Stoelben, E.; Neumaier, B.; Thomas, R. K.; Dietlein, M.; Wolf, J.: Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. Journal of Clinical Oncology 29 (13), pp. 1701 - 1708 (2011)
2010
Journal Article
Ansen, S.; Bangard, C.; Querings, S.; Gabler, F.; Scheffler, M.; Seidel, D.; Saal, B.; Zander, T.; Nogova, L.; Töpelt, K. et al.; Markert, E.; Stoelben, E.; Ernestus, K.; Thomas, R. K.; Wolf, J.: Osteoblastic response in patients with non-small cell lung cancer with activating EGFR mutations and bone metastases during treatment with EGFR kinase inhibitors. Journal of Thoracic Oncology 5 (3), pp. 407 - 409 (2010)
Journal Article
Bill, A.; Schmitz, A.; Albertoni, B.; Song, J.-N.; Heukamp, L. C.; Walrafen, D.; Thorwirth, F.; Verveer, P. J.; Zimmer, S.; Meffert, L. et al.; Schreiber, A.; Chatterjee, S.; Thomas, R. K.; Ullrich, R. T.; Lang, T.; Famulok, M.: Cytohesins are cytoplasmic ErbB receptor activators. Cell 143 (2), pp. 201 - 211 (2010)
Journal Article
Chmielecki, J.; Peifer, M.; Jia, P.; Socci, N. D.; Hutchinson, K.; Viale, A.; Zhao, Z.; Thomas, R. K.; Pao, W.: Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Research 38 (20), pp. 6985 - 6996 (2010)
Journal Article
Pawar, V. G.; Sos, M. L.; Rode, H. B.; Rabiller, M.; Heynck, S.; van Otterlo, W. A. L.; Thomas, R. K.; Rauh, D.: Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. Journal of Medicinal Chemistry 53 (7), pp. 2892 - 2901 (2010)
Journal Article
Peifer, M.; Weiss, J.; Sos, M. L.; Koker, M.; Heynck, S.; Netzer, C.; Fischer, S.; Rode, H.; Rauh, D.; Rahnenführer, J. et al.; Thomas, R. K.: Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS ONE 5 (1), p. e8919 - e8919 (2010)
Journal Article
Sheng, Q.; Liu, X.; Fleming, E.; Yuan, K.; Chen, J.; Moustafa, Z.; Thomas, R. K.; Greulich, H.; Schinzel, A. C.; Zaghlul, S. et al.; Batt, D.; Ettenberg, S.; Meyerson, M.; Schoeberl, B.; Kung, A. L.; Hahn, W. C.; Drapkin, R.; Livingston, D. M.; Liu, J.: An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17 (10), pp. 298 - 310 (2010)
Journal Article
Sos, M. L.; Rode, H. B.; Heynck, S.; Peifer, M.; Fischer, F.; Klüter, S.; Pawar, V. G.; Reuter, C.; Heuckmann, J. M.; Weiss, J. et al.; Ruddigkeit, L.; Rabiller, M.; Koker, M.; Simard, J. R.; Getlik, M.; Yuza, Y.; Chen, T.-H.; Greulich, H.; Thomas, R. K.; Rauh, D.: Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research 70 (3), pp. 868 - 874 (2010)
Journal Article
Weiss, J.; Sos, M. L.; Seidel, D.; Peifer, M.; Zander, T.; Heuckmann, J. M.; Ullrich, R. T.; Menon, R.; Maier, S.; Soltermann, A. et al.; Moch, H.; Wagener, P.; Fischer, F.; Heynck, S.; Koker, M.; Schöttle, J.; Leenders, F.; Gabler, F.; Dabow, I.; Querings, S.; Heukamp, L. C.; Balke-Want, H.; Ansén, S.; Rauh, D.; Baessmann, I.; Altmüller, J.; Wainer, Z.; Conron, M.; Wright, G.; Russell, P.; Solomon, B.; Brambilla, E.; Brambilla, C.; Lorimier, P.; Sollberg, S.; Brustugun, O. T.; Engel-Riedel, W.; Ludwig, C.; Petersen, I.; Sänger, J.; Clement, J.; Groen, H.; Timens, W.; Sietsma, H.; Thunnissen, E.; Smit, E.; Heidemann, D.; Cappuzzo, F.; Ligorio, C.; Damiani, S.; Hallek, M.; Beroukhim, R.; Pao, W.; Klebl, B.; Baumann, M.; Buettner, R.; Ernestus, K.; Stoelben, E.; Wolf, J.; Nürnberg, P.; Perner, S.; Thomas, R. K.: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2 (62), p. 62ra93 - 62ra93 (2010)
Journal Article
Zhu, C.-Q.; Ding, K.; Strumpf, D.; Weir, B. A.; Meyerson, M.; Pennell, N.; Thomas, R. K.; Naoki, K.; Ladd-Acosta, C.; Liu, N. et al.; Pintilie, M.; Der, S.; Seymour, L.; Jurisica, I.; Shepherd, F.; Tsao, M.-S.: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. Journal of Clinical Oncology 28 (29), pp. 4417 - 4424 (2010)
2009
Journal Article
Sos, M. L.; Thomas, R. K.: Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle 8 (22), pp. 3652 - 3656 (2009)
Journal Article
Barbie, D. A.; Tamayo, P.; Boehm, J. S.; Kim, S. Y.; Moody, S. E.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Meylan, E.; Scholl, C. et al.; Fröhling, S.; Chan, E. M.; Sos, M. L.; Michel, K.; Mermel, C.; Silver, S. J.; Weir, B. A.; Reiling, J. H.; Sheng, Q.; Gupta, P. B.; Wadlow, R. C.; Le, H.; Hoersch, S.; Wittner, B. S.; Ramaswamy, S.; Livingston, D. M.; Sabatini, D. M.; Meyerson, M.; Thomas, R. K.; Lander, E. S.; Mesirov, J. P.; Root, D. E.; Gilliland, D. G.; Jacks, T.; Hahn, W. C.: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (7269), pp. 108 - 112 (2009)
Journal Article
Ramos, A. H.; Dutt, A.; Mermel, C.; Perner, S.; Cho, J.; Lafargue, C.; Johnson, L. A.; Stiedl, A.-C.; Tanaka, K. E.; Bass, A. J. et al.; Barretina, J.; Weir, B. A.; Beroukhim, R.; Thomas, R. K.; Minna, J. D.; Chirieac, L. R.; Lindeman, N. I.; Giordano, T.; Beer, D. G.; Wagner, P.; Wistuba, I. I.; Rubin, M. A.; Meyerson, M.: Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy 8 (21), pp. 2042 - 2050 (2009)
Journal Article
Sos, M. L.; Fischer, S.; Ullrich, R.; Peifer, M.; Heuckmann, J. M.; Koker, M.; Heynck, S.; Stueckrath, I.; Weiss, J.; Fischer, F. et al.; Michel, K.; Goel, A.; Regales, L.; Politi, K. A.; Perera, S.; Getlik, M.; Heukamp, L. C.; Ansen, S.; Zander, T.; Beroukhim, R.; Kashkar, H.; Shokat, K. M.; Sellers, W. R.; Rauh, D.; Orr, C.; Hoeflich, K. P.; Friedman, L.; Wong, K.-K.; Pao, W.; Thomas, R. K.: Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America 106, pp. 18351 - 18356 (2009)
Go to Editor View